HYFT Share Price Performance
US$1.31
-0.68 (-34.17%)
30.3% undervalued intrinsic discount
US$1.88
Fair Value
Price US$1.31
Talos US$1.88
AnalystHighTarget US$5.00
AnalystLowTarget US$3.00
Fair ValueUS$1.88
Share Pricen/a
Narrative Update • Jul 30
MindWalk Holdings Corp. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 82 Fair Values set on narratives written by author
HYFT Community Narratives
TA
Fair Value
·Fair Value US$1.88 30.3% undervalued intrinsic discount
The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
10users have liked this narrative
0users have commented on this narrative
46users have followed this narrative
AN
Fair Value
·Fair Value US$5 73.8% undervalued intrinsic discount
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value
·Fair Value US$3 56.3% undervalued intrinsic discount
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
MindWalk Holdings is no longer just a lab-for-hire business—it’s shifting into software that helps drug teams learn from biology data, and the market may not be treating it that way yet. The story hinges on whether its LensAI platform keeps landing sticky enterprise customers and whether its drug programs attract partners without forcing shareholders to fund the bill.Read more
TA
US$1.88
30.3% undervalued intrinsic discount
Fair Value
Step 1: 2031 Financial Output
2031 Net Income = 65,000,000 x 22.0% = 14,300,000 CAD
2031 Target Market Cap = 14,300,000 x 25.0= 357,500,000 CAD
Step 2: Diluted Per-Share Metrics (83,752,002 Shares)
2031 Diluted EPS = 14,300,000 CAD / 83,752,002 Shares = 0.1707 CAD
2031 Diluted Share Price = 0.1707 x 25x = 4.268 CAD
Step 3: Discounting to Present Value
Discount Factor = 1 / (1 + 0.10)^5 =0.62092
Present Diluted Fair Value =4.268 CAD x 0.62092 = 2.650 CAD = 1.88 USD (0.71 fx rate)
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
Key Takeaways Increasing adoption of AI-driven platforms and regulatory shifts boost growth prospects, but competition, compliance complexity, and sector consolidation could pressure margins and pricing. Operational improvements and platform differentiation support earnings, yet macroeconomic risks and service commoditization may limit margin expansion and recurring growth.Read more
AN
US$3
56.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.7%
Future PE
33.51x
Price in 2028
US$2.05
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
Key Takeaways AI-powered platforms and regulatory tailwinds uniquely position the company for outsized margin expansion, industry leadership, and sustained revenue surprises beyond analyst expectations. Streamlined operations and a focused, platform-driven strategy will accelerate service adoption, high-value contract wins, and recurring revenue growth in biologic drug development.Read more
AN
US$5
73.8% undervalued intrinsic discount
Fair Value
Profit Margin
18.72%
Future PE
55.89x
Price in 2028
US$3.41
AI-Driven Discovery Will Advance Biologic Drug Development
Key Takeaways Accelerated adoption of AI-driven platforms and regulatory changes are boosting demand for ImmunoPrecise's scalable, high-margin discovery and screening services. Strategic partnerships, operational efficiencies, and core market expansion are supporting recurring revenue growth, improved margins, and stronger long-term earnings stability.Read more
AN
US$4
67.3% undervalued intrinsic discount
Fair Value
Profit Margin
16.63%
Future PE
52.75x
Price in 2028
US$2.73
Trending Discussion
No trending discussion available.
Recently Updated Narratives
TA
Re-Evaluating MindWalk Holdings: Cash Runway Realities and Fair Value Calculations
Fair Value: US$1.88 30.3% undervalued intrinsic discount
46 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
Fair Value: US$3 56.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
Fair Value: US$5 73.8% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MindWalk Holdings Corp. Key Details
About HYFT
- Founded
- 1983
- Employees
- 76
- CEO
- WebsiteView website
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
